secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001689548-25-000118
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

PRAX gets FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor
--------------------------------------------------------------------------------

- Ulixacaltamide granted BTD for treatment of essential tremor based on Essential3 Phase 3 data.
- BTD enables expedited development and regulatory review for serious condition.
- Positive topline data from two pivotal Phase 3 studies supported the designation.
- Essential tremor affects millions; ulixacaltamide may show substantial improvement over available therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000118/0001689548-25-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000118/prax-20251229.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer